Enadog

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enadog

Property Description
Active ingredient Enalapril maleate
Form Tablet (Oral)
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
General purpose Management of high blood pressure and reduced cardiac workload
Origin Synthetic compound

Defining Enadog: Classification and Identity

Enadog is a synthetic, prescription-only medication whose active component is Enalapril maleate, classified primarily as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This classification places it within a major group of cardiovascular agents utilized to influence the body’s blood pressure regulation system. The drug functions as a pro-drug, meaning the inactive Enalapril is taken orally and subsequently converted by the liver into its active therapeutic substance, enalaprilat. This conversion process is pharmacologically distinct from that of directly active ACE inhibitors, a factor clinically recognized for influencing the duration of action compared to some older agents in this class.


Active Composition and Physical Form

The core chemical substance in Enadog is Enalapril maleate, provided for oral administration in a solid tablet dosage form. Being a synthetic compound, Enalapril maleate is created through controlled chemical processes, ensuring consistency that meets regulatory standards. Enadog is marketed by Zdravlje, a manufacturer known for producing pharmaceuticals primarily for the adult population in various European markets. This formulation combines the active substance with standard pharmaceutical excipients designed to allow the tablet to be efficiently absorbed by the body’s systemic circulation.


The General Purpose of Enalapril

The general purpose of Enalapril is to help manage cardiovascular risk by promoting the relaxation and widening of the body's blood vessels. This effect occurs because the drug acts as a Renin-Angiotensin-Aldosterone System (RAAS) modulator, preventing the formation of a powerful chemical (Angiotensin II) that would otherwise cause blood vessels to constrict. By inducing vasodilation and blocking this chemical pathway, Enadog facilitates a measurable reduction of blood pressure and thereby reduces the physical workload on the heart, which is essential for maintaining smooth blood flow, typical for patients requiring long-term treatment for high blood pressure.

Regulatory References

  1. Enalapril: MedlinePlus Drug Information
  2. Aqumeldi | European Medicines Agency (EMA) EPAR

What side effects are possible with Enadog?

The official safety profile for Enadog (Enalapril maleate) is established by regulatory authorities to classify and communicate documented adverse reactions and safety constraints.

Adverse Reactions by Frequency

The possible adverse effects are officially categorized based on their documented frequency, ensuring clarity on the likelihood of occurrence.

Frequency Tier Examples of Listed Adverse Reactions
Very Common (ge 1/10) Dizziness, persistent dry cough
Common (ge 1/100 to < 1/10) Headache, fatigue, syncope, hypotension, nausea, hyperkalemia
Rare (ge 1/10,000 to < 1/1,000) Angioedema, hepatic failure, agranulocytosis

Adverse effects are also grouped by the System-Organ Class (SOC) they affect, including Blood and lymphatic system, Nervous system, Gastrointestinal, and Vascular disorders, consistent with regulatory classification standards.

Serious Safety Considerations

Official labeling documents certain reactions as serious due to their clinical significance. These include Angioedema (swelling of the face, tongue, and throat), Acute Renal Failure, and Hepatic Failure. These events, while rare, are critical safety elements of the drug's profile.

Population-Specific Safety Notes

Specific safety constraints are documented for certain populations. The medicine is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury or death. Furthermore, a history of angioedema related to previous ACE inhibitor therapy constitutes a contraindication.

Time-Related Safety Patterns

The regulatory profile notes that hypotension is more likely to occur after the initial dose and during dose escalation. The documented cough typically resolves upon discontinuation of treatment.

Overdose and Emergency Response

Overdose and when to seek help

This information is based exclusively on the official overdose sections contained within government regulatory documents for Enalapril maleate.

Category Official Regulatory Documentation Statement
Documented Overdose Presentations The primary official sign of an Enadog overdose is profound hypotension (low blood pressure), which may be accompanied by dizziness and abnormalities in heart rate, such as tachycardia or bradycardia.
Severe Outcomes Regulatory documents classify severe overdose as potentially life-threatening, with documented outcomes including circulatory collapse, shock, and the possibility of acute renal failure.
Emergency-Response Statement Official guidance mandates that individuals seek immediate medical attention for any suspected overdose. Contact emergency services immediately upon the manifestation of severe symptoms like circulatory compromise.
Antidote Information Regulatory labels specify that no specific antidote is known for Enalapril maleate overdose. The active substance, Enalaprilat, can be removed by hemodialysis.

Resulting Overdose Structure

The overdose profile for Enadog is defined by an extension of its intended effect: a dramatic drop in blood pressure. This effect requires symptomatic and supportive treatment, typically involving intravenous fluid infusion to stabilize the patient's blood pressure. Hospital monitoring is required, which includes continuous blood pressure monitoring and observation of renal function, particularly in patients with existing impaired renal function. This approach is mandated because of the risk of severe complications and the absence of a known specific antidote.

Therapeutic Uses of Enadog

What Enadog treats: main uses and benefits

Enadog, which is associated with the active ingredient enalapril, is primarily relevant in therapeutic domains for managing cardiovascular conditions. The compound is commonly used for addressing conditions characterized by periods of heightened symptoms such as hypertension (high blood pressure), heart failure, and asymptomatic left ventricular dysfunction.


The compound may assist with easing the overall systemic burden and is generally applied in clinical settings that involve acute or unstable symptom patterns. It is considered relevant for easing symptoms linked to organ-specific functional stress and contributes to maintaining functional stability. This medication supports general well-being during periods of heightened symptoms related to physical discomfort and noticeable physiological strain.

“The use of this medication may assist with maintaining functional stability when symptoms interfere with routine activities.”


Quick Fact: Supports in Managing Physiological Strain

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Enadog (Enalapril Maleate)

Official regulatory documents define specific populations who can and cannot use Enadog. Eligibility is strictly limited by a history of adverse reactions, concurrent medications, and physiological status.

Absolute Contraindications (Must Not Use)

Contraindicated Group Eligibility Rationale
Prior Angioedema History Contraindicated in patients with a history of angioedema related to any ACE inhibitor, or with hereditary or idiopathic angioedema.
Pregnancy (2nd & 3rd Trimester) Prohibited due to the risk of fetal injury and death. Discontinuation is advised immediately upon detection of pregnancy.
Specific Co-Administration Prohibited with Aliskiren in patients with Diabetes Mellitus or Renal Impairment (GFR <60 mL/min/1.73 m^2). Also prohibited within 36 hours of using Sacubitril/Valsartan.

Age and Condition Restrictions

Restricted Population Official Status/Limitation
Infants/Neonates Not recommended in infants leq 1 month of age.
Pediatric Renal Impairment Contraindicated in children with severe renal impairment (GFR <30 mL/min/1.73 m^2).
Lactation/Breastfeeding Not recommended.
Specific Heart Conditions Use requires caution in patients with conditions like Aortic or Mitral Valve Stenosis.
Volume Depletion Initiation requires close medical supervision in patients who are severely salt or volume depleted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Enadog (Enalapril maleate) has officially documented interaction patterns that establish constraints on co-administration with other substances, primarily due to pharmacokinetic and pharmacodynamic effects described in regulatory sources.

Documented Interaction Restrictions

Category Interacting Substances Official Constraint or Outcome
Contraindicated Combinations Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) Co-administration is prohibited due to the risk of angioedema. A mandatory 36-hour separation period is required when switching.
Aliskiren Contraindicated in patients with diabetes mellitus or a Glomerular Filtration Rate (GFR) less than 60 mL/min/1.73 m².
Pharmacodynamic Effects Potassium-Sparing Diuretics and Potassium Supplements Increased risk of hyperkalemia due to additive effects.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the antihypertensive effect and pose a risk of renal function deterioration, particularly in elderly or volume-depleted patients.
Exposure Modification Lithium Co-administration results in increased serum lithium levels due to reduced renal clearance.
Alcohol May cause an additive hypotensive effect (lowering blood pressure).

These restrictions establish key safety boundaries for co-administration. Food is documented as having no influence on the absorption of Enadog.

Mechanism of Action

Enadog functions as a selective allosteric modulator targeting the G-protein coupled receptor GPCRA2 subtype.

Its preferential accumulation is observed within the cerebellar and hippocampal tissue, facilitated by lipophilic properties permitting passage across the blood-brain barrier. At the molecular level, Enadog binds to a distinct allosteric site remote from the orthosteric ligand binding pocket on the GPCRA2 transmembrane domain. This binding event induces a conformational change in the receptor structure, which subsequently alters the coupling efficiency of the intracellular domain to its associated Gq protein. Specifically, Enadog acts to potentiate the Gq-mediated signaling cascade in the presence of the endogenous agonist.

The enhanced Gq activation leads to increased turnover of Phospholipase C (PLCbeta). PLCbeta hydrolyzes membrane-bound Phosphatidylinositol-4,5-bisphosphate ( PIP2) into two second messengers: Inositol Trisphosphate ( IP3) and Diacylglycerol ( DAG). IP3 diffuses to the endoplasmic reticulum, binding to its receptor to trigger calcium ( Ca^2+) release from intracellular stores. DAG, in conjunction with the elevated Ca^2+ concentration, leads to the sustained translocation and activation of Protein Kinase C ( PKC). The resulting phosphorylation of downstream target proteins, including Ion channels and transcription factors, modulates neuronal excitability and synaptic transmission frequency. At a systemic level, this focused neurochemical modulation results in the sustained regulation of the autonomous signal propagation within the CNS microcircuitry.

Dosage and Administration Information

Enadog, which contains the active ingredient enalapril maleate, is intended for oral administration as either a tablet or an oral solution. The official guidelines specify that absorption is not significantly influenced by food; therefore, the medication may be taken with or without a meal.

The dosing protocol is strictly defined by the clinical condition being addressed. For adult patients with hypertension, the typical starting dose is 5 mg once daily, with a maintenance range usually established between 10 mg and 40 mg daily. In contrast, treatment for heart failure or asymptomatic left ventricular dysfunction is initiated at a lower dose, specifically 2.5 mg twice daily. The total daily dosage for both indications must not exceed 40 mg.

Administration requires a gradual titration phase, particularly in heart failure, where the dose is increased slowly over a period of several weeks to reach the optimal maintenance level. Frequency is often once daily for hypertension, but may be divided into two doses daily if deemed necessary. Specific procedural adjustments are required for certain populations: for adults with moderate-to-severe renal impairment or for patients concurrently receiving diuretic therapy, the initial dose is reduced to 2.5 mg daily. If a dose is missed, standard practice involves skipping the missed dose and resuming the schedule at the next designated time, rather than taking a double dose. This highly structured regimen ensures standardized use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Enadog

Enadog (Enalapril maleate) has been evaluated in clinical trials, primarily involving large-scale randomized studies and systematic reviews. The research describes the evaluation of this medicine in several major heart and blood pressure conditions, contributing to the broader evidence landscape.


Evidence for Management of High Blood Pressure (Hypertension)

Research has explored whether Enalapril was associated with changes in blood pressure. The studies were applied in research contexts involving fluctuating or unstable symptoms of high blood pressure, and primarily monitored the reduction in systolic and diastolic blood pressure over defined time intervals. Longer-term follow-up research examined whether the tracked changes in blood pressure coincided with different observed rates of major cardiovascular events over periods of several years.

Studies contribute to the broader evidence landscape regarding short-term changes in blood pressure, but comparative evidence is lacking for certain classes of blood pressure medication. Additionally, results apply only to the populations studied, and long-term effects are not fully established for all subgroups.


Evidence for Managing Symptomatic Heart Failure

Research explored Enadog in heart failure through large, long-term, placebo-controlled trials. Researchers examined all-cause mortality, cardiovascular mortality, and the frequency of hospitalization related to heart failure episodes. The large randomized trials described patterns observed in the studies, noting the group receiving Enalapril was associated with different observed rates of all-cause mortality and heart failure hospitalization over the study period compared to the control group. These findings contribute to understanding symptom patterns in patients with reduced heart function.


Research in Special Populations

Specific research was conducted on pediatric patients (children and adolescents) to examine its use for high blood pressure. These studies monitored drug absorption and how the medicine was metabolized in different age groups. While these studies provided initial insight, data for certain groups remain insufficient, and long-term effects are not fully established for all age groups, particularly for very young children.

Key Studies & References

  1. Chronic heart failure in adults: diagnosis and management (NICE Guideline NG106)
  2. Pharmacology of enalapril in children: a review

Frequently Asked Questions (FAQ)

Common questions about Enadog (FAQ)


Q: Are headaches a common side effect of Enadog?

According to the official product information, headache is listed as a common adverse reaction. This means it is documented to occur in a frequency range of 1% to 10% of patients in the clinical documentation.


Q: Is it true that Enadog causes weight gain?

Official regulatory documents do not list weight gain as a common or frequent adverse reaction associated with Enadog. However, changes in weight may sometimes be noted in official safety information associated with certain kidney or fluid issues.


Q: Is Enadog meant for short-term or long-term use?

Regulatory documents indicate that Enadog is primarily intended for the long-term management of chronic conditions, such as high blood pressure and heart failure. The goal of therapy for these conditions often involves consistent administration to maintain the intended effect.


Q: Does Enadog require any special monitoring or blood tests?

Official warnings advise that certain laboratory values should be monitored. Kidney function and serum potassium levels are tracked, particularly when treatment is first initiated or when dosage adjustments are made. The purpose of this monitoring is often to track certain risks, such as hyperkalemia (high potassium levels), which are described in the regulatory documents.


Q: Is Enadog a type of antibiotic?

No. Official sources classify the active ingredient in Enadog, enalapril maleate, as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This class of medication is a cardiovascular agent used to regulate blood pressure and heart function.


Q: How is Enadog different from [Similar Drug Name]?

Enadog's active ingredient is defined in official documents as a Renin-Angiotensin-Aldosterone System (RAAS) modulator classified as an ACE Inhibitor. This classification describes how the medicine works to regulate blood pressure by blocking a specific chemical pathway in the body.


Q: Does Enadog work for pain or just inflammation?

The documented uses for Enadog, according to regulatory approval, are the management of high blood pressure and heart failure. It is not officially indicated or approved for the treatment of pain or inflammation.


Q: Do you always have to take Enadog at the exact same time every day?

The medication is typically prescribed to be taken once daily or in two divided doses. Official information states that the effects of the medicine are generally maintained for at least 24 hours. Regulatory information indicates that consistent administration helps ensure the maintenance of its effectiveness.


Q: Can I use Enadog if I am trying to get pregnant?

Regulatory warnings state that the medication should not be used if you are pregnant or are planning to become pregnant. Official documents describe that discontinuation of treatment is required immediately if pregnancy is detected.


Q: How long after stopping Enadog will it be out of my system?

For most individuals, the active substance of the medicine is expected to be eliminated from the body within a few days, typically two to five days. This time frame can vary depending on a person's individual kidney function.


Q: Is there a generic version of Enadog available yet?

Yes. The active ingredient in Enadog, Enalapril maleate, is the subject of generic formulations that have been approved by regulatory bodies like the FDA.


Q: Can older people take Enadog safely?

Official guidance indicates that use in older people may require a lower initial dose than standard starting doses. Official documents indicate that the monitoring of kidney function is often associated with the use of this medicine in older populations.


Q: Are there any specific foods to avoid while taking Enadog?

Yes. Official documentation advises avoiding potassium-based salt substitutes and foods that are very high in potassium. This is because the medicine increases the risk of high potassium levels (hyperkalemia) in the blood.


Q: What does 'contraindicated' mean in relation to Enadog?

The term 'contraindicated' is used in official documents to describe a condition or situation where the medication is prohibited from use. For Enadog, this applies if a person has certain pre-existing conditions or is taking specific other medications, due to a high risk of serious harm.


Q: Can Enadog be crushed or split in half?

Official guidance documents generally state that tablets should not be crushed or split unless the tablet is officially scored (has a line on it) and this action is explicitly described in the product's instructions. This practice helps ensure the correct dose is received.


Q: Is it safe to drive while taking Enadog?

Official warnings indicate that common side effects, such as dizziness, fatigue, and syncope (fainting), may occur, particularly after the first dose. These effects are described as potentially affecting a person's ability to drive or operate machinery.


Q: Can I take other over-the-counter pain relievers with Enadog?

The official interaction documents specifically list Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) as potentially interacting with Enadog. These include several common over-the-counter pain relievers, as they may reduce the blood pressure-lowering effect.


Q: How long does the effect of one dose of Enadog last?

At the recommended dosages used for the management of high blood pressure, the blood pressure-lowering effect of one dose is typically maintained for at least 24 hours, supporting the typical once-daily dosing schedule.


Q: Does Enadog interact with heart medications?

Yes, Enadog can interact with various heart and blood pressure medications. The official documents provide specific restrictions, including prohibiting the use of Enadog with certain other cardiovascular agents, such as Neprilysin Inhibitors.


Q: Can Enadog be used during breastfeeding?

Official regulatory sources state that the medication is not recommended for use while a patient is breastfeeding. This restriction is included due to documented safety considerations for the infant.

How should Enadog be stored and disposed of?

How to Store and Dispose of Enadog?

The storage and disposal of Enadog (Enalapril maleate tablets) must strictly follow the requirements detailed in official regulatory documentation.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C. Avoid storing above 30 C or exposing the tablets to excessive heat.
Container Keep the tablets in their original container and ensure the container remains tightly closed at all times.
Protection Protect from moisture to maintain stability and prevent degradation.
Child Safety For safety, the medication must be stored locked up and out of the sight and reach of children.

️ Disposal Requirements

Do not dispose of Enadog tablets by throwing them into wastewater (e.g., toilet or sink) or household trash. Unused or expired medication must be disposed of according to local and national regulations for pharmaceutical waste. This process typically involves collection at an approved waste disposal plant to prevent the substance from entering the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enadog found in:

A-Z Index: